Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Ampyra - labeled renal guidance
Product / population
Dalfampridine (Ampyra), oral extended-release tablets for adult MS
Renal method
Cockcroft-Gault creatinine clearance, mL/min
Source revision
DailyMed SPL version 22, effective 2026-01-16; posted Jan 23, 2026
At CrCl <=50 mL/min, Ampyra is contraindicated. At 51-80, weigh walking benefit against the risk of seizures from increased exposure. Determine CrCl before treatment and at least annually. Swallow tablets whole. A lower-strength renal regimen is unavailable.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
